|From: DonaldTrump (Rep: 0)||Date: 10/19/2004 11:27|
|Forum: Politics - Msg #58 - List AVN msgs ||No Thread (Rec: 0) |
|AVANIR (AVN) MERGER OR BUYOUT ON IT'S WAY??? |
Recent SEC filings for key employee retention rights seems to indicate an AVN merger.
The stock could soar but will shareholders keep AVN's subsidiary Xenerex and AVN's anthrax antibody? It appears to be preparation for a merger or maybe even a buyout. Alot of questions can be raised but you can bet if there is a buyout, it better be in the high double digits or shareholders will go after them as AVN has a Phase 3 drug almost ready to go with remarkable results thus far and an anthrax antibody created.
Either way, at less than $10 per share now, AVN looks like the best buy around. Lazard just issued a BUY on AVN. This is very impressive!
for more info on AVN go to http://www.avanir.com & http://www.xenerex.com
AVANIR PHARMACEUTICALS filed this from their recent 8-K
Item 1.01. Entry into a Material Definitive Agreement.
On September 17, 2004, Avanir Pharmaceuticals (the "Company") entered into Retention Agreements with eight key employees (the "Employees"). The form of Retention Agreement (the "Agreement") and a list of the Employees is attached hereto as Exhibit 99.1. The Agreement provides certain severance benefits to each respective Employee if his or her employment is terminated following a "change of control" (as defined) of the Company. These severance benefits will be paid only if: (i) the change of control occurs prior to September 30, 2005, (ii) the termination of employment occurs within 12 months following the change of control, and (iii) the termination was without "cause" or was a "resignation for good reason" (as such terms are defined). If these conditions are met for a given Employee, he or she will receive severance payments equal to twelve months of base salary, plus an amount equal to the aggregate bonus payment(s) received by such Employee in the Company's preceding fiscal year. Additionally, he or she will have the ability to extend the exercise period of outstanding stock option awards, such that they will remain exercisable for 12 months from the date of termination.
After careful review, I am covinced that the technology employed by AVN's subsidiary is distinctively superior than that employed by their two biggest competitors of ABGX and PDLI. There are a few smaller companies as well that can't even begin to compare. I believe that AVN is completely undervalued and their Xenerex subsidiary alone will be worth more than ABGX, PDLI and all the lessor companies combined. Other than that, AVN itself has one of the most impressive drug development pipelines with a potential blockbuster in Phase 3 and demonstrating undisputably impressive results. Given a bit more time, AVN will hit a grand slam if all falls into place. If anyone hasn't already done so, do check out the data on AVN's anthrax antibody antidote. It will make you think about the potential of AVN in fighting cancer and infectious diseases in the future. AVN is a very solid company and completely undervalued.
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 2020- TheLion.com, Inc.